Thiosulfate in urine as a facilitator in the diagnosis of prostate cancer for patients with prostate-specific antigen less or equal 10 ng/mL

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 9, 2013, Pages 1825-1831

  Chwatko, Grazyna ^a   Forma, Ewa ^a   Wilkosz, Jacek ^b   Głowacki, Rafał ^a   Jóźwiak, Paweł ^a   Rózański, Waldemar ^a   Bryś, Magdalena ^a   Krześlak, Anna ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

High performance liquid chromatography (HPLC); Prostate cancer; Prostate specific antigen (PSA); Thiosulfate

Indexed keywords

CREATININE; PROSTATE SPECIFIC ANTIGEN; THIOSULFATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CREATININE URINE LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVERSED PHASE LIQUID CHROMATOGRAPHY; URINALYSIS; URINE;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; THIOSULFATES; YOUNG ADULT;

EID: 84888123233     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0069     Document Type: Article

References (31)

1. Roobol MJ, Haese A, Bjartell A. Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol 2011;50(Suppl 1): 85-9.
2. Strope SA, Andriole GL. Prostate cancer screening: current status and future perspectives. Nat Rev Urol 2010;7: 487-93.
3. Berretta R, Moscato P. Cancer biomarker discovery: the entropic hallmark. PLoS One 2010;18:e12262.
4. Couzin J. Biomarkers. Metabolite in urine may point to high-risk prostate cancer. Science 2009;323:865.
5. Durand M, Weinstein P. Thiosulfate in human urine following minor exposure to hydrogen sulfide: implications for forensic analysis of poisoning. Forensic Toxicol 2007;25: 92-5.
6. Kage S, Takekawa K, Kurosaki K, Imamura T, Kudo K. The usefulness of thiosulfate as an indicator of hydrogen sulfide poisoning: three cases. Int J Legal Med 1997;110: 220-2. (Pubitemid 27323778)
7. Lavu M, Bhushan S, Lefer, DJ. Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential. Clin Sci 2010;120: 219-29.
8. Whiteman M, Moore PK. Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability? J Cell Mol Med 2009;13: 488-507.
9. Whiteman M, Winyard PG. Hydrogen sulfide and inflammation: the good, the bad, the ugly and the promising. Expert Rev Clin Pharmacol 2011;4: 13-32.
10. Gong QH, Shi XR, Hong ZY, Pan LL, Liu XH, Zhu YZ. A new hope for neurodegeneration: possible role of hydrogen sulfide. J Alzheimers Dis 2011;24: 173-82.
11. Whiteman M, Gooding KM, Whatmore JL, Ball CI, Mawson D, Skinner K, et al. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia 2010;53: 1722-6.
12. Cole DE, Evrovski J. Screening for sulfite oxidase deficiency with urinary thiosulfate/sulfate ratios determined by anion chromatography. Clin Chem 1996;42: 654-5. (Pubitemid 26111892)
13. Belardinelli MC, Chabli A, Chadefaux-Vekemans B, Kamoun P. Urinary sulfur compounds in Down syndrome. Clin Chem 2001;47: 1500-1. (Pubitemid 32678842)
14. Torun M, Bayhan A, Yentür G. Response of allergic and normal persons to sulfiting agents in wine: determination of thiosulfate excretion in urine. Clin Chem 1989;35: 1792-3. (Pubitemid 19212465)
15. Baskar R, Bian J. Hydrogen sulfide gas has cell growth regulatory role. Eur J Pharmacol 2011;656: 5-9.
16. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179: 1587-92.
17. Chwatko G, Bald E. Determination of thiosulfate in human urine by high performance liquid chromatography. Talanta 2009;79: 229-34.
18. Shi H, Ma Y, Ma Y. A simple and fast method to determine and quantify urinary creatinine. Anal Chim Acta 1995;312: 79-83.
19. Jung K. Enzyme activities in urine: how should we express their excretion? A critical literature review. Eur J Clin Chem Clin Biochem 1991;29: 725-9.
20. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457: 910-4.
21. Cai WJ, Wang MJ, Ju LH, Wang C, Zhu YC. Hydrogen sulfide induces human colon cancer cell proliferation: role of Akt, ERK and p21. Cell Biol Int 2010;34: 565-72.
22. Cao Q, Zhang L, Yang G, Xu C, Wang R. Butyrate-stimulated H2S production in colon cancer cells. Antioxi Redox Signal 2010;12: 1101-9.
23. Guo H, Gai JW, Wang Y, Jin HF, Du JB, Jin J. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells. Urology 2012;79:483.e1-5.
24. Łowicka E. Bełtowski J. Hydrogen sulfide (H2S) - the third gas of interest for pharmacologists. Pharmacol Rep 2007;59: 4-24. (Pubitemid 46522698)
25. Ramasamy S, Singh S, Taniere P, Langman MJ, Eggo MC. Sulfidedetoxifying enzymes in human colon are decreased in cancer and upregulated in differentiation. Am J Physiol Gastroinvest 2006;191: 288-96.
26. Lee F, Torp-Pedersen S, Littrup PJ, McLeary RD, McHugh TA, Smid AP, et al. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. Radiology 1989;170: 29-32. (Pubitemid 19016839)
27. Crawford ED, Leewansangtong S, Goktas S, Holthaus K, Baier M. Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/mL and age-specific reference range as a cut-off for abnormal values. Prostate 1999;3841: 296-302. (Pubitemid 29119795)
28. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardio PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151: 1283-90. (Pubitemid 24121936)
29. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147: 817-21.
30. Ciatto S, Bonardi R, Mazzotta A, Lombardi C, Santoni R, Cardini S, et al. Comparing two modalities of screening for prostate cancer: digital rectal examination+transrectal ultrasonography vs. prostate-specific antigen. Tumori 1995;81: 225-9.
31. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004;350: 2239-46.